8-K: Greenwich LifeSciences Provides Update on Phase III Breast Cancer Trial, Flamingo-01, Expands Patient Enrollment

Greenwich LifeSciences has provided an update on its Phase III clinical trial, Flamingo-01, for its breast cancer immunotherapy, GLSI-100, including expansion of the trial to include more patients and sites.

Summary

• Greenwich LifeSciences has provided an update on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences.
• The Data Safety Monitoring Board (DSMB) has recommended the study continue without modifications after meeting twice in 2023.
• No serious adverse events related to GLSI-100 have been reported to date.
• The trial currently includes approximately 30 clinical sites with 87 locations in the US, with plans to add up to 10 more sites in 2024.
• Pending European regulatory approval, the company plans to add 105-120 sites in Europe, bringing the total potential sites to 140-160.
• The trial is designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, requiring 28 events for the primary analysis.
• An interim analysis will be conducted when at least 14 events have occurred.
• The company plans to expand the third arm of the trial to include 250 non-HLA-A*02 patients, up from the original 100.
• The first three commercial lots of GP2 active ingredient have been completed, which could produce approximately 200,000 doses.
• The company is preparing a comprehensive study report of the Phase II trial for the FDA prior to filing a BLA.
• The company is also considering additional clinical trials, including extending the follow-up of the Phase IIb trial and a trial for all low-risk HER2 positive patients.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the progress of the clinical trial, expansion plans, and potential market opportunity. However, there are some concerns about data inconsistencies and the need for further investigation, which temper the overall sentiment.

Positives

• The Data Safety Monitoring Board (DSMB) has recommended the study continue without modifications.
• No serious adverse events related to GLSI-100 have been reported.
• The trial is expanding to include more sites in the US and Europe, potentially increasing patient enrollment.
• The expansion of the third arm to 250 patients will allow for a broader understanding of GLSI-100's efficacy.
• The completion of the first three commercial lots of GP2 is a significant step towards commercialization.
• The company is actively preparing for the filing of a BLA with the FDA.
• The company is exploring additional clinical trials to further expand the use of GP2.

Negatives

• The company has identified inconsistencies in the Phase II trial data, requiring further investigation with HJF and clinical sites.
• A potential recurrence in the treated arm of the Phase II trial was not initially reported, which could impact the p-value.
• The company did not have direct control over the Phase II trial data collection and reporting, which has led to some data discrepancies.
• The interim analysis may be modified to include an additional sizing interim analysis before enrollment ends.

Risks

• The company is reliant on the cooperation of HJF and clinical sites to finalize the Phase II trial data.
• Inconsistencies in the Phase II trial data could potentially impact the regulatory approval process.
• The success of the Phase III trial is not guaranteed, and the interim analysis may not yield positive results.
• The company needs additional funding and resources to pursue additional clinical trials.
• The company is dependent on European regulatory approval to expand the trial into Europe.

Future Outlook

The company anticipates adding more clinical sites in the US and Europe, potentially reaching peak enrollment by the end of 2024. They also plan to file a BLA for GLSI-100 and are considering additional clinical trials to expand the use of GP2.

Management Comments

• Dr. Rimawi, Chair of the Steering Committee, commented, 'Among my peers, the level of interest in the Flamingo-01 trial is very high.'
• Dr. Rimawi also stated, 'The new sites in Europe will make significant contributions to the trial in terms of patient enrollment as well as overall conduct of the trial.'
• Dr. Rimawi further added, 'The expansion of the unblinded non-HLA-A*02 arm is also significant as it reflects the interest among patients and investigators in exploring the activity of GLSI-100 in these patients, which may expand the patient population who could benefit from this exciting vaccine.'
• Dr. Jaye Thompson, VP Clinical and Regulatory Affairs, commented, 'We welcome the new US and European members to the Steering Committee and are honored to be receiving their continued guidance in the development of GP2 and oversight of Flamingo-01.'
• CEO Snehal Patel commented, 'With the addition of the European sites and approximately 150 total sites, peak enrollment rates could be reached by the end of 2024 allowing for a refinement in the interim analysis.'
• Mr. Patel also stated, 'Using the early Phase III trial data to reaffirm the size of the arms of the Phase III trial may be the best information we could use to reduce risk and improve the chances of success of Flamingo-01.'
• Mr. Patel further added, 'While we may have high expectations for the interim analysis midway through the trial, Roches successful Herceptin and Kadcyla products reduced recurrences by only 50%, while still requiring that all HER2 positive patients be treated. Thus, we believe a similar clinical outcome for Flamingo-01 could occur and could generate similar returns to stakeholders as did Roches franchise drugs, which at their peak significantly exceeded $5 billion in revenue per year.'
• Mr. Patel commented, 'We have experienced significant interest from investors, strategics, analysts, and regulators in the 5 year follow-up data we published and the 3 and 4 year follow-up data independently published by the clinical investigators.'
• Mr. Patel added, 'While a recurrence in the control arm would decrease the p-value and still result in a 100% reduction in the recurrence rate, a recurrence in the treated arm would increase the p-value and would result in an 80% reduction in the recurrence rate. In either case, we believe that the reduction in recurrence rate is clinically meaningful and substantial compared to the approximately 20-50% reduction in recurrences of all other approved breast cancer drugs for this patient population.'
• Mr. Patel further commented, 'If successful, vaccinating HER2 positive patients who are long term survivors or are at low risk for recurrence could more than double the patient population being pursued in Flamingo-01.'

Industry Context

This announcement is significant in the context of the biopharmaceutical industry, as it provides an update on the progress of a Phase III clinical trial for a novel breast cancer immunotherapy. The expansion of the trial into Europe and the inclusion of more patients reflects the growing interest in this type of treatment. The comparison to Roche's Herceptin and Kadcyla highlights the potential market opportunity for GLSI-100 if successful.

Comparison to Industry Standards

• The document compares the potential of GLSI-100 to Roche's Herceptin and Kadcyla, which achieved a 50% reduction in recurrence rates and generated over $5 billion in annual revenue at their peak.
• The company aims for a 70% reduction in recurrence rate with GLSI-100, based on the trial design, and notes that the Phase II trial showed an even greater reduction.
• The document mentions that other approved breast cancer drugs for this patient population have shown approximately 20-50% reduction in recurrences, suggesting that GLSI-100 could be a significant improvement if successful.
• The trial design is based on a hazard ratio of 0.3, which is a common metric used in oncology clinical trials to assess the effectiveness of a treatment.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical trial and the potential for regulatory approval and commercialization of GLSI-100.
• Patients with HER2/neu positive breast cancer may benefit from the development of GLSI-100.
• Employees of Greenwich LifeSciences will be involved in the ongoing clinical trial and regulatory processes.
• Clinical sites and healthcare professionals will be involved in the trial and potential future use of GLSI-100.
• Investors, strategics, analysts, and regulators are showing significant interest in the company's progress.

Next Steps

• The company will continue to enroll patients in the Flamingo-01 trial.
• The company will add up to 10 additional sites in the US in 2024.
• The company will seek European regulatory approval to add 105-120 sites in Europe.
• The company will expand the third arm of the trial to 250 patients.
• The company will conduct an interim analysis when at least 14 events have occurred.
• The company will prepare a comprehensive study report of the Phase II trial for the FDA.
• The company will file a BLA for GLSI-100.
• The company will consider additional clinical trials, including extending the follow-up of the Phase IIb trial and a trial for all low-risk HER2 positive patients.

Key Dates

Keywords

GLSI-100, GP2, Flamingo-01, Breast Cancer, Immunotherapy, Clinical Trial, HER2/neu, Phase III, Data Safety Monitoring Board, BLA, FDA, Recurrence, Commercialization